Rheonix Executive Named a Fellow of National Academy of Clinical Biochemistry

ITHACA, N.Y. – Richard A. Montagna, Ph.D., senior vice president for scientific and clinical affairs at Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been accepted as a Fellow of the National Academy of Clinical Biochemistry (NACB). Fellowship in NACB is open to members of the American Association of Clinical Chemistry (AACC) who are doctoral-level clinical scientists.

Fellows must hold American Board of Clinical Chemistry or equivalent board certification and be active in research, education or service in clinical biochemistry, or have at least 10 years of postdoctoral experience in clinical biochemistry plus distinguished achievements in research, education or service and be recognized for outstanding contributions to the field. "I'm pleased to be a part of the NACB as we all seek to develop more effective diagnostics. I'm equally pleased to work alongside the very talented and committed scientists and engineers at Rheonix as we strive together to make that goal a reality," Montagna said.

Montagna has more than 35 years of leadership experience and has managed the commercialization of more than 40 biotechnology products. He has published over 40 scientific papers, holds a number of patents in the biosensor area and is an adjunct professor in the department of biological and environmental engineering at Cornell University.

Composed of leading scientists, NACB is dedicated to advancing the science and practice of laboratory medicine by advocating for scholarship through scientific research; by promoting scientific discovery, application and integration through educational programs; and by publishing Laboratory Medicine Practice Guidelines (LMPG), which applies clinical biochemistry to medical diagnosis and therapy.

For more information on Rheonix and the Rheonix CARD, please visit www.rheonix.com.

About Rheonix: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx(tm) platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD(R) cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.

Christopher Powers
Public Relations Account Manager
Pinckney Hugo Group
760 West Genesee Street
Syracuse, NY 13204
cpowers@pinckneyhugo.com

  • <<
  • >>